SIRT1

CCM Biosciences Announces Launch of Protein Upregulation Business Unit

Retrieved on: 
Wednesday, September 20, 2023
Medicinal chemistry, National academy, SIRT1, University, Chemical physics, Mitochondrion, Bioorganic & Medicinal Chemistry, Enzyme, NAD, Mutation, RNA, Infertility, Cystic fibrosis, SIRT3, Alzheimer's disease, University of Palermo, Parkinson's disease, Protein, CCM, Publication, Journal, Patient, PLOS, Biophysics, Fertility, The Journal of Chemical Physics, Regulation, Cystic Fibrosis Foundation, Physics, Longevity, Notifiable disease, IND, Gene, Sirtuin, Library, Messenger, Dietary supplement, Pharmaceutical industry, Vaccine

MOUNT LAUREL, N.J., Sept. 20, 2023 /PRNewswire/ -- CCM Biosciences, a pharmaceutical discovery and development company that recently confirmed its launch from stealth, today announced its latest business unit — CCM Protein Upregulation — dedicated to advancing first-in-class drug leads for age-related conditions such as Alzheimer's, Parkinson's, and infertility as well as for genetically inherited diseases such as cystic fibrosis, using highly differentiated technology platforms for improving the enzymatic activity or expression level of critical proteins implicated in the pathogenesis of such disorders. 

Key Points: 
  • New business unit is focused on "undruggable" targets for age-related indications and genetically inherited diseases.
  • Enhancement of the activity or expression level of proteins is important for the treatment of many age-related and genetically inherited conditions.
  • Such compounds have the potential to rejuvenate the activity of SIRT3 to levels observed in youth," said Dr. Raj Chakrabarti, CEO of CCM Biosciences.
  • CCM Protein Upregulation's drug leads represent a first-in-class opportunity to treat multiple diseases caused by nonsense mutations.

Huntington's Disease Market Spotlight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 18, 2022
Health, Biotechnology, Ageing, Patient, Central nervous system, Peroxisome proliferator-activated receptor gamma, Disease, CNS, Probability, NMDA, Pfizer, SIRT1, PPAR, Bausch Health, HD, MAP, Huntington's disease, Learning disability, Huntingtin, JHD, CAG, Psychiatry, Valbenazine, Dementia, Pharmaceutical industry, Teva

The "Market Spotlight: Huntington's Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Huntington's Disease" report has been added to ResearchAndMarkets.com's offering.
  • Huntington's disease (HD) is a rare disorder of the central nervous system (CNS) which causes the degeneration of nerve cells.
  • It is an autosomal dominant disease characterized by involuntary choreatic movements, psychiatric and behavioral disturbances, and dementia.
  • The length of the CAG repeats is inversely associated with the age of disease onset - the longer the repeat, the earlier the onset.

Dr. David Sinclair Joins Levels as Advisor

Retrieved on: 
Tuesday, October 12, 2021
Medical Devices, Health, Technology, Diabetes, Fitness & Nutrition, Software, Lazarus, Harvard Medical School, NAD, Book, Memory, Biotechnology, National, Biology, CGM, Diabetes, Time, Department of Genetics, University of Cambridge, SpaceX, Cancer, TIME, Research, Chromatin, Commonwealth Writers, Molecular genetics, Technology, CR, Neurodegeneration, Prediabetes, Calorie, Google, Sleep, University, Resveratrol, Awareness, Leadership, Diet, Food, Multimedia, SIRT1, Regeneration, Respiration (physiology), Mammal, Exercise, Stanford University, Sirtuin, Department, Doctor of Philosophy, Health, Longevity, Mitochondrion, Microdeletion syndrome, Learning, Partnership, Science, Biomarker, Pharmaceutical industry, News, Medical device

Levels , the first biosensor system to give real-time feedback on nutrition and lifestyle, today announced that leading longevity scientist Dr. David Sinclair has joined the company as a Levels Advisor .

Key Points: 
  • Levels , the first biosensor system to give real-time feedback on nutrition and lifestyle, today announced that leading longevity scientist Dr. David Sinclair has joined the company as a Levels Advisor .
  • Dr. Sinclair has been at the forefront of the latest discoveries in understanding why we age and how to slow its effects.
  • Dr. Sinclair joins an unprecedented group of thought leaders, clinicians, and researchers in metabolic health, and his expertise will help to drive awareness to the metabolic health crisis through content development and research in partnership with the Levels team.
  • View the full release here: https://www.businesswire.com/news/home/20211012005133/en/
    Dr. David Sinclair Joins Levels as Advisor (Photo: Business Wire)
    Im excited to work with Levels Health to empower people with the tools to optimize their bodies and help achieve longer healthspans and lifespans, says Dr. Sinclair.